Abstract
18F-Labelled fluoroazomycin arabinoside ([18F]FAZA) is a 2-nitroimidazole (azomycin) based PET tracer used extensively in cancer clinics to diagnose tumour hypoxia. The hypoxia-specific uptake and rapid blood clearance kinetics of FAZA contribute to good tumor-to-background ratios (T/B ratios) and high image contrast. However, FAZA, an α- configuration nucleoside, is not transported by cellular nucleoside transporters. It enters cells only via diffusion, therefore not achieving the high uptake and T/B ratios characteristic of actively transported radiopharmaceuticals. The present work describes the synthesis, physicochemical properties and preliminary assessment of the radiosensitization properties of two novel azomycin nucleosides, 1-β-D-(2-deoxy-2-fluoroarabinofuranosyl)-2-nitroimidazole (β-2-FAZA) and 1-β-D-(3- deoxy-3-fluorolyxofuranosyl)-2-nitroimidazole (β-3-FAZL) (fluorination yields 60% and 55%, respectively). The tosylated precursors required to synthesize the corresponding F-18 labeled radiopharmaceuticals are also reported. The partition coefficients (P) for β-2-FAZA (1.0) and β-3-FAZL (0.95) were marginally lower than reported for FAZA (1.1). The radiosensitization properties of both these compounds are similar to that of FAZA, with sensitizer enhancement ratios (SER) of ∼1.8 for HCT-116 cells.
Keywords: Tissue hypoxia, cancer, azomycin nucleosides, FAZA, β-analogs, radiosensitization
Medicinal Chemistry
Title: Synthesis and Hypoxia Selective Radiosensitization Potential of β-2-FAZA and β-3-FAZL: Fluorinated Azomycin β-Nucleosides
Volume: 5 Issue: 2
Author(s): P. Kumar, S. Emami, Z. Kresolek, J. Yang, A. J.B. McEwan and L. I. Wiebe
Affiliation:
Keywords: Tissue hypoxia, cancer, azomycin nucleosides, FAZA, β-analogs, radiosensitization
Abstract: 18F-Labelled fluoroazomycin arabinoside ([18F]FAZA) is a 2-nitroimidazole (azomycin) based PET tracer used extensively in cancer clinics to diagnose tumour hypoxia. The hypoxia-specific uptake and rapid blood clearance kinetics of FAZA contribute to good tumor-to-background ratios (T/B ratios) and high image contrast. However, FAZA, an α- configuration nucleoside, is not transported by cellular nucleoside transporters. It enters cells only via diffusion, therefore not achieving the high uptake and T/B ratios characteristic of actively transported radiopharmaceuticals. The present work describes the synthesis, physicochemical properties and preliminary assessment of the radiosensitization properties of two novel azomycin nucleosides, 1-β-D-(2-deoxy-2-fluoroarabinofuranosyl)-2-nitroimidazole (β-2-FAZA) and 1-β-D-(3- deoxy-3-fluorolyxofuranosyl)-2-nitroimidazole (β-3-FAZL) (fluorination yields 60% and 55%, respectively). The tosylated precursors required to synthesize the corresponding F-18 labeled radiopharmaceuticals are also reported. The partition coefficients (P) for β-2-FAZA (1.0) and β-3-FAZL (0.95) were marginally lower than reported for FAZA (1.1). The radiosensitization properties of both these compounds are similar to that of FAZA, with sensitizer enhancement ratios (SER) of ∼1.8 for HCT-116 cells.
Export Options
About this article
Cite this article as:
Kumar P., Emami S., Kresolek Z., Yang J., McEwan J.B. A. and Wiebe I. L., Synthesis and Hypoxia Selective Radiosensitization Potential of β-2-FAZA and β-3-FAZL: Fluorinated Azomycin β-Nucleosides, Medicinal Chemistry 2009; 5 (2) . https://dx.doi.org/10.2174/157340609787582945
DOI https://dx.doi.org/10.2174/157340609787582945 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diffusion-Weighted MRI for Assessment of Early Cancer Treatment Response
Current Pharmaceutical Biotechnology Molecular Targeting of Lymphatics for Therapy
Current Pharmaceutical Design An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Percutaneous Dilatational Tracheostomy - An Update
Current Respiratory Medicine Reviews Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Improving Brain Drug Targeting Through Exploitation of The Nose-to- Brain Route: A Physiological and Pharmacokinetic Perspective
Current Drug Delivery Molecular-Targeted and Cell-Based Therapies for Sjogren’s Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Laparoscopic Reconstructive Surgery in Pediatric Urology: An Overview of Current Options
Current Pediatric Reviews Translational Research: A Future Strategy for Managing Squamous Cell Carcinoma of the Head and Neck?
Anti-Cancer Agents in Medicinal Chemistry Radiotracers in Oncology
Current Radiopharmaceuticals OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Clinical Significance of Umami Taste and Umami-Related Gene Expression Analysis for the Objective Assessment of Umami Taste Loss
Current Pharmaceutical Design Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery